O’Regan Weighs Escalation, De-Escalation Approaches in Early-Stage HER2+ Breast Cancer
In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer
Related Articles
Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer
Anne Favret, MD discusses the FDA approval of capivasertib in combination with fulvestrant for HR-positive, HER2-negative breast cancer.
Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer
The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.
MRD-Negative CR Separates Ponatinib From the Rest in Newly Diagnosed, Ph+ ALL
Ibrahim Aldoss, MD, discussed the FDA approval of ponatinib plus chemotherapy in newly diagnosed, Ph-positive acute lymphoblastic leukemia.
Nanatinostat With Valganciclovir Produces Positive Topline Data in EBV+ PTCL
Nanatinostat plus valganciclovir generated antitumor activity in patients with EBV-positive PTCL in the NAVAL-1 trial.
Glofitamab Plus Chemotherapy Meets OS Primary End Point in Relapsed/Refractory DLBCL
Glofitamab plus chemotherapy generated an overall survival improvement vs rituximab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups
Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.
Retrospective Study Highlights Evolving Community Use of BTK Inhibitors for CLL/SLL
A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.
First-Line Rucaparib Maintenance Provides Long-Term Benefits in Newly Diagnosed Ovarian Cancer
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.